A randomised controlled trial of Rivaroxaban for the prevention of major cardiovascular events in patients with coronary or peripheral artery disease (COMPASS- Cardiovascular OutcoMes for People using Anticoagulation StrategieS) - Long-Term Open-Label Extension (LTOLE).
A phase 1b, randomized, double-blind, placebo-controlled, multi-center, single-ascending dose study to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of DS-1040b when added to standard of care anticoagulation therapy in subjects with acute submassive pulmonary embolism
Characterization of patients following acute venous thromboembolism (VTE) and safety and effectiveness of dabigatran etexilate (DE) in the treatment and secondary prevention of acute deep vein thrombosis (DVT) and pulmonary embolism (PE) in comparison to vitamin K antagonist (VKA) in routine clinical practice
An international, multicenter, randomized, double-blind, placebo controlled phase 3 trial investigating the efficacy and safety of rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheral artery disease undergoing lower extremity revascularization procedures
Recurrent venous thromboembolism risk stratification evaluation. Validation of the "Men and HERDOO2" - a clinical decision rule to identify patients with "unprovoked" venous thromboembolism who can discontinue anticoagulants after six months of treatment